Long-term Effectiveness of 9-δ-tetrahydrocannabinol:Cannabidiol Oromucosal Spray in Clinical Practice: results from a 18-months Multicenter Italian Study

Francesco Patti1, Clara Chisari2, Emanuele D’Amico3, Claudio Solaro4, Sebastiano Arena5, Pasquale Annunziata5, Maria Donata Benedetti6, Eliana Berra7, Assunta Bianco8, Roberto Bruno Bossio9, Fabio Buttari10, Letizia Castelli11, Paola Cavalla12, Raffaella Cerqua13, Gianfranco Costantino14, Federica Esposito15, Claudio Gasperini16, Angelica Guareschi17, Matilde Inglese18, Domenico Ippolito19, Roberta Lanzillo20, Giorgia Teresa Maniscalco21, Manuela Matta22, Damiano Paolicelli23, Loredana Petrucci24, Simona Pontecorvo25, Isabella Righini26, Edoardo Sessa27, Francesco Sacca28, Giovanna Salamone29, Elisabetta Signorilli30, Gabriella Spinicci31, Daniele Litterio A. Spitaleri32, Eleonora Tavazzi33, Maria Trotta34, Mauro Zaffaroni35, Mario Zappia3

1"GF Ingrassia"section of Neurosciences, University of Catania, 2"GF Ingrassia" section of Neurosciences, University of Catania, 3University of Catania, 4Neurology PA Micone Hospital, 5University of Siena, 6University of Verona, 7Department of Neurology - Neurology Institute C. Mondino, Pavia, Italy, 8Institute of Neurology, Catholic University, Fondazione Policlinico Universitario A. Gemelli, 9Azienda Sanitaria Provinciale di Cosenza, 10Multiple Sclerosis Clinical and Research Unit, Department of Systems Medicine, Tor Vergata University, 11Multiple Sclerosis Centre, S. Andrea Hospital, 12University of Turin, 13Neurological Clinic, Department of Experimental and Clinical Medicine, Marche Polytechnic University, 14Ospedali Riuniti di Foggia, 15Laboratory of Genetics of Complex Neurological Disorders, Institute of Experimental Neurology (INSPE), Division of Neuroscience, San Raffaele Scientific Institute, 16San Camillo-Forlanini Hospital, 17Ospedale San Raffaele, 18University of Genoa, 19Department of Medical, Surgical, Neurological, Metabolic and Aging Sciences, Second University of Naples, 20Department of Neurosciences, Reproductive and Odontostomatological Sciences, University Federico II, Naples, 21Department of Neurology, Ospedale Cardarelli, 22Neurobiology Unit, Neurologia 2, CReSM (Regional Referring Center Multiple Sclerosis), San Luigi Gonzaga University Hospital & Neuroscience Institute Cavaleri Ottolenghi (NICO), 23Department of Basic Medical Sciences, Neurosciences and Sense Organs, University of Bari Aldo Moro, 24University Hospital Pisa, 25University of Rome, 26University of Florence, 27IRCCS-Bonino Pulejo Centre, 28University Federico II, 29Villa Sofia-Cervello Hospital, 30Second University of Naples, 31ASL n.8 Ospedale Binaghi Centro Sclerosi Multipla, 32A.O. "S. Giuseppe Moscati", 33Instituto Mondino, 34University "Magna Graecia, 35Gallarate Hospital

Objective:
We aimed to provide real life data on clinical outcomes of a large population of Italian patients with treatment-resistant multiple sclerosis (MS) spasticity receiving 9-δ-tetrahydrocannabinol and cannabidiol (THC:CBD) oromucosal spray (Sativex®).

Background:
THC:CBD oromucosal spray is used as mono or add-on therapy for moderate to severe MS spasticity resistant to other medications.

Design/Methods:
This 18-months observational, prospective, multicentre study evaluated patients with resistant MS spasticity treated with THC:CBD according to approved labelling. Data were collected from the mandatory Italian medicines agency (AIFA) e-registry from January 2015 to June 2018. Spasticity assessment with the 0-10 numerical rating scale (NRS) was performed at baseline, after 1 month of treatment (T1) and every 6 months until 18 months (T4) from the treatment initiation.

Results:
A total of 1845 patients were recruited from 32 Italian MS centres. At T1, 1502 (81.4%) of patients reached an NRS improvement of ≥20% and 814 (40.2%) a of ≥30%, with a mean NRS score reduction of 28.9% at T1 and of 36.8% at T4. Daily number of puffs was generally stable through the observation period (6.9±2.4 at T1 vs 6.9±3.1 at T4, p=0.8). At T4, 727 (39.4%) patients have discontinued treatment; 388 (53.4%) because of lack of effectiveness and 339 (46.6%) for adverse events: 127 (37.5%) reported vertigo, 118 (34.8%) sleepiness, 96 (28.3%) worsening of fatigue, and 54 (15.9%) cognitive symptoms. The multivariate analysis showed that higher NRS score at baseline (OR 2.21 95% CI 1.12-6.28, p<0.01) and higher difference of NRS between T1 and baseline (OR 2.03 95%CI 1.04-8.14, p<0.05) were associated to an increased probability to stay on therapy after 18 months.

Conclusions:
Real-life data from a large Italian MS population confirmed the long-term effectiveness of THC:CBD for the treatment of resistant MS spasticity in everyday clinical practice. Treatment effects were sustained for 18-months with a relatively stable number of puffs/day.